1. Home
  2. TK vs INBX Comparison

TK vs INBX Comparison

Compare TK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Teekay Corporation

TK

Teekay Corporation

HOLD

Current Price

$12.90

Market Cap

937.1M

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$63.92

Market Cap

999.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TK
INBX
Founded
1973
2010
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
937.1M
999.7M
IPO Year
1995
2024

Fundamental Metrics

Financial Performance
Metric
TK
INBX
Price
$12.90
$63.92
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
501.7K
169.7K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
15.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.43
N/A
Revenue Growth
N/A
550.00
52 Week Low
$5.83
$10.81
52 Week High
$13.76
$94.57

Technical Indicators

Market Signals
Indicator
TK
INBX
Relative Strength Index (RSI) 64.02 43.47
Support Level $8.99 $57.30
Resistance Level $13.76 $85.97
Average True Range (ATR) 0.47 4.57
MACD 0.08 0.28
Stochastic Oscillator 98.31 41.88

Price Performance

Historical Comparison
TK
INBX

About TK Teekay Corporation

Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: